RP
Regeneron Pharmaceuticals
Resolving
Resolving brand mentions across new media
Regeneron Pharmaceuticals
Resolving brand mentions across new media
Regeneron Pharmaceuticals
7
Mentions
73.9K
Views
“Discussed for a 10% stock decline following a failed Phase 3 clinical trial.”
“Biotech company whose stock plunged nearly 10% after a failed melanoma drug trial.”
“Biopharma company whose stock dropped 12% after a failed skin cancer drug trial.”
“Biopharma company whose stock dropped 12% after a failed skin cancer drug trial.”
Arcmira media summary
Arcmira tracks where Regeneron Pharmaceuticals is discussed across indexed YouTube videos, transcripts, channels, and related entities.
Discussed for a 10% stock decline following a failed Phase 3 clinical trial.
Biotech company whose stock plunged nearly 10% after a failed melanoma drug trial.
Biopharma company whose stock dropped 12% after a failed skin cancer drug trial.
Biopharma company whose stock dropped 12% after a failed skin cancer drug trial.
Acquired 23andMe out of bankruptcy.
Arcmira tracks 7 indexed media appearances or mentions for Regeneron Pharmaceuticals, tied to source videos, channels, and transcript-derived context.
Arcmira uses indexed YouTube videos and transcripts. Representative source evidence on this page includes "Seagate Slips, NextEra Lower, Regeneron Tumbles | Stock Movers" with transcript-derived context and links when available.
Regeneron Pharmaceuticals is connected to SPACs, Energy Sector M&A, Airline Fuel Costs in Arcmira's media graph.